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Patients with myeloid malignancies and either the
3q21q26 syndrome or t(1;3)(p36;q21) have been reported
to share similar clinicopathological features and a
common molecular mechanism for leukemogenesis. Over-
expression of MDS1/EVI1 (3q26) or MEL1/PRDM16
(1p36), both members of the PR-domain family, has been
directly implicated in the malignant transformation of this
subset of neoplasias. The breakpoints in both entities are
outside the genes, and the 3q21 region, where RPN1 is
located, seems to act as an enhancer. MEL1 has been
reported to be expressed in leukemia cells with t(1;3) and
in the normal uterus and fetal kidney, but neither in bone
marrow (BM) nor in other tissues, suggesting that this
gene is speciﬁc to t(1;3)-positive MDS/AML. We report
the molecular characterization of a t(1;3)(p36;q21) in a
patient with MDS (RAEB-2). In contrast to previous
studies, we demonstrate that MEL1, the PR-containing
form, and MEL1S, the PR-lacking form, are widely
expressed in normal tissues, including BM. The clinico-
pathological features and the breakpoint on 1p36 are
different from cases previously described, and MEL1 is
not overexpressed, suggesting a heterogeneity in myeloid
neoplasias with t(1;3).
Oncogene (2004) 23, 311–316. doi:10.1038/sj.onc.1206923
Keywords: PRDM16/MEL1; RPN1; 1p36; 3q21; MDS
(RAEB)
The 3q21q26 syndrome is associated with myelodys-
plastic syndrome (MDS) or acute myeloid leukemia
(AML), and is characterized by trilineage dysplasia, in
particular dysmegakaryocytopoiesis, and poor prog-
nosis (Secker-Walker et al., 1995). A similar type of
MDS/AML has been reported in the recurrent
t(1;3)(p36;q21). Patients with both entities seem to share
similar clinicopathological features and a common
molecular mechanism. The leukemogenic mechanism
in these aberrations has been suggested to be the ectopic
expression of EVI1 in patients with inv(3)(q21q26) and
t(3;3)(q21;q26), and ofMEL1/PRDM16 in patients with
t(1;3)(p36;q21) (Mochizuki et al., 2000), in both cases
for juxtaposition with regulatory sequences of the
housekeeping gene RPN1. The breakpoints (BPs) are
outside the genes in most cases, and the 3q21 region,
where RPN1 is located, seems to act as an enhancer,
activating the transcription of these genes. MDS1-EVI1
(3q26) and MEL1 (1p36) are members of the family of
PR-domain genes along with RIZ1/PRDM2 (1p36),
BLIMP-1/PRDM1 (6q21) and PFM1/PRDM4 (12q23)
(Schneider et al., 2002). The protein products of these
genes are involved in human cancer in an unusual yin-
yang fashion. It seems that two products are normally
produced from a PR-domain family member, which
differ by the presence or absence of the PR domain; the
PR-plus product is disrupted or underexpressed,
whereas the PR-minus product is present or over-
expressed in cancer cells. This imbalance in the amount
of the two products, a result of either genetic or
epigenetic events, appears to be an important cause of
malignancy (Huang, 1999).
MEL1 (1p36.3) encodes a zinc-ﬁnger protein that
shares 63% sequence similarity to MDS1-EVI1, with a
similar domain structure. Mochizuki et al. (2000)
reported that MEL1 is expressed in leukemia cells with
t(1;3) but not in normal bone marrow (BM), suggesting
that the ectopic expression of MEL1 is speciﬁc to the
t(1;3)-positive MDS/AML. Recently, the same group
has identiﬁed two different MEL1 products of 170 and
150 kDa by immunoblotting analysis, designated as full-
length MEL1 and short-form MEL1S, respectively
(Nishikata et al., 2003). Like MDS1-EVI1 and EVI1,
two mRNAs with and without the PR domain would be
transcribed from this locus. MEL1 is the PR-containing
form, with the PR domain coded from codon ATC91
(exon 2) to codon CCC223 (exon 5) (Mochizuki et al.,
2000), and MEL1S is the PR-lacking form initiated from
an internal codon ATG599 (exon 9) (Nishikata et al.,
2003). The fusion of MEL1 or MEL1S to GAL4
DNA-binding domain made them GAL4-bindingReceived 6 May 2003; revised 19 June 2003; accepted 26 June 2003
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site-dependent transcriptional repressors. Moreover,
overexpression of MEL1S blocked granulocytic differ-
entiation induced by G-CSF in IL-3-dependent murine
myeloid L-G3 cells, while MEL1 could not block the
differentiation. From these results, they conclude that
overexpression of MEL1S could be one of the causative
factors in the pathogenesis of t(1;3)-positive myeloid
leukemia cells (Nishikata et al., 2003). Here, we report
the molecular characterization of a translocation
t(1;3)(p36;q21) in a patient with MDS (RAEB-2). The
clinicopathological features and the BP on 1p36 are
different from AML cases previously described, and
MEL1 is not overexpressed in our patient, suggesting a
heterogeneity in cases with t(1;3). We also report the
pattern of expression of MEL1 and MEL1S, which we
show is different from that previously described.
G banding and FISH analysis showed a single clone
46,XX,t(1;3)(p36;q21) in the karyotype of a patient with
MDS (Figure 1). This 75-year-old woman was admitted
because of leukocytosis, anemia and thrombocytopenia
in June 1998. On physical examination, remarked
bilateral edema, multiple bruises and petechiae and
pallor, without hepatosplenomegaly or gingival swel-
ling, was observed. BM examination showed hyperplas-
tic marrow with an increased level of myeloblasts with
monocytoid differentiation (18.6%). Refractory anemia
with excess of blasts (RAEB-2) was diagnosed in the
presence of 16% blasts. Treatment with cytosine-
arabinoside, idarubicin and etoposide was started, but
the patient died 6 months later of respiratory distress.
Fifteen BAC and PACs located on 1p36.3 and nine
on 3q21 were used in metaphase FISH experiments. The
BP on chromosome 1 was located between RP11-
181G12 and RP11-740P5 (Figure 2a). RP3-395M20,
located between the two BACs that deﬁned the BP,
was deleted. Therefore, we could deﬁne the BP on
1p36.3 located 300 kb telomeric to MEL1, and a
cryptic deletion of less than 400 kb was detected
(Figure 1b). The molecular characterization of similar
translocations was ﬁrst described by Mochizuki et al.
in four patients with AML-M4 (Mochizuki et al., 2000);
the BP on 1p36 was located in a 90-kb cluster telomeric
to MEL1. Recently, Xinh et al. (2003) deﬁned the
localization of the BPs on 1p36 in two of these cases,
and in a new patient with t(1;3). In the two patients
reported by Mochizuki et al. (2000), the BP was in RP5-
907A6 (BR-2), 78.4-kb telomeric to MEL1; in the new
patient, who presented an unusual clinical proﬁle, the
BP was located in RP1-163G9 (BR-1), in the ﬁrst intron
ofMEL1. Both BPs are centromeric to the BP we deﬁne
in our patient with RAEB, that it is located 250 kb
telomeric to ARPM2 and 300 kb telomeric to MEL1
(Figure 2a). This suggests a heterogeneity in cases with
t(1;3), which could reﬂect the clinical features. The
diagnosis of our patient was RAEB, the subtype most
frequent (42.8%) among cases with MDS and t(1;3),
whereas Xinh et al. deﬁned the BP in three patients with
AML-M4, the most frequent FAB subtype (53.8%)
among cases with AML and t(1;3) (Xinh et al., 2003).
The clinicopathological proﬁle is also different in our
patient, suggesting that not all cases sharing t(1;3) are
similar to the 3q21q26 syndrome, and that a different
molecular mechanism could be present in this patient.
The BP in chromosome 3 was between RP11-525K18
and RP11-475N22 (Figure 2b). Both probes showed a
small signal on the der(3) and der(1), respectively,
suggesting that part of these chromosome 3 probes is
deleted. Probes located between 525K18 and 475N22
showed no signal neither on der(3) nor on der(1),
conﬁrming that a region of about 500 kb is deleted
(Figure 1c). Although the 3q21 BPs in cases with t(1;3)
have been reported to cluster speciﬁcally in a region of
50 kb (BCR-C), centromeric to the 30 kb BCR of
3q21q26 syndrome cases (BCR-T), both downstream
of the RPN1 gene (Shimizu et al., 2000), a recent review
revealed that in six cases with inv(3), four with t(3;3) and
three with t(1;3), the BP was in BCR-C and in nine cases
with inv(3), seven with t(3;3) and three with t(1;3) in
BCR-T (Wieser, 2002). Therefore, both BCR may be
affected by these alterations. The BP in our patient with
t(1;3) and RAEB was less than 100 kb centromeric to
GR6 and RPN1, in the BCR-C region. 30RACE
experiments with primers in GR6 showed no new
sequences (data not shown). This is the ﬁrst time that
both, 1p36 and 3q21 BPs, have been deﬁned in a
t(1;3)(p13;q21).
On the basis of the positional relationship between
MDS1-EVI1 and MEL1, Mochizuki et al. (2000)
suggested that both genes are transcriptionally activated
by the translocation of the 3q21 region with RPN1.
Figure 1 G banding and FISH analysis of a patient with
t(1;3)(p36;q21). (a) Partial G-band karyotype. Arrows indicate
BPs of rearranged chromosomes. (b) RP11-740P5 probe (green)
from chromosome 1 labels normal chromosome 1 and der(1). RP3-
395M20 probe (red) from chromosome 1 labels only normal 1,
indicating that this region is deleted in the der(1). (c) RP11-689D3
probe (red) and RP11-475N22 (green) from chromosome 3 label
normal chromosome 3 and der(1). The small green signal on der(1)
suggests that part of this chromosome 3 probe is deleted. DNA
from BAC and PAC clones was extracted using Qiapreps Spin
Miniprep kit (Qiagen, Hilden, Germany), and labeled with
Spectrum Greens and Spectrum Oranges (Vysis, Downers Grove,
IL, USA) by nick translation. FISH analysis was performed on BM
metaphases as previously described (Odero et al., 2001)
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Mochizuki et al. (2000) reported thatMEL1 is expressed
in the uterus, fetal kidney, and speciﬁcally in leukemia
cells with t(1;3), but not in other cell lines or in normal
BM, spleen, or fetal liver, suggesting that the ectopic
expression of MEL1 is speciﬁc to the t(1;3)-positive
MDS/AML (Mochizuki et al., 2000). The MEL1 gene
codes for two products that differ in the presence or
absence of the PR domain. In order to distinguish the
expression pattern of these two forms, we designed two
sets of primers. We used primers MEL1N-F and
MEL1N-R, located outside the PR-domain sequence,
in a region conserved in all the splicing variants, to
amplify the region common to MEL1 and MEL1S
(cMEL). It is not possible to discriminate between these
two products, since MEL1S is contained in the MEL1
sequence. Primers MEL1PR-F and MEL1PR-R were
designed in exon 3 and exon 5, respectively, that code
for the PR domain, to amplify only MEL1 (Figure 3a).
Primer sequences are shown in Table 1. We analysed the
expression pattern of MEL1 and cMEL (MEL1 plus
MEL1S) by RT–PCR separately on CD34þ cells, BM
and peripheral blood (PB) of a healthy donor, normal
uterus, and in BM of the patient. All reactions showed
bands of 260 and 200 bp, as expected for MEL1 and
cMEL ampliﬁcations, respectively, with the primers
used (Figure 3a, b). Sequence analysis of the RT–PCR
products conﬁrmed these results. We also ampliﬁed
MEL1 and cMEL in a set of ﬁrst-strand cDNAs from
eight human tissues: heart, brain, placenta, lung, liver,
skeletal muscle, kidney and pancreas. The expression
was detected in all the tissues of the panel, being
stronger in the heart, lung, kidney and pancreas
(Figure 3b). Therefore, MEL1 and MEL1S were
expressed in at least 11 normal tissues, including BM
and PB, and in the BM of the patient. The set of primers
used for Mochizuki et al. (2000) did not discriminate
between MEL1 and MEL1S; hence, their analysis really
showed the expression of the region shared by both
transcripts. The differences in these results could be
explained because the RT–PCR conditions Mochizuki
Figure 2 Integrate map of the 1pter-1p36.3 and 3q21 regions showing the ideograms of chromosomes 1 and 3 with the FISH results of
a patient with t(1;3)(p36;q21). The physical map and relative size and position of genes involved in human cancer and of the clones
used in this study (GenBank Accession number in brackets) are shown in the diagram. The clones were obtained from libraries from
the Roswell Park Cancer Institute (Buffalo, NY, USA). (a) The BP on 1p36.3 in the patient with t(1;3) was located between RP11-
181G12 and RP11-740P5. We found a cryptic deletion of less than 400 kb. BR-1 and BR-2: BPs of three patients with t(1;3) and AML-
M4, described by Xinh et al. (2003). (b) The BP in chromosome 3 was between RP11-525K18 and RP11-475N22
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et al. used are more restrictive (30 versus 35 cycles),
although in their experiments both Northern and RT–
PCR showed the same results. However, our experi-
ments showed a strong expression of MEL1 and cMEL
in the heart, lung, kidney and pancreas, which should
have been easily detected by Mochizuki et al.
(Figure 3b). Interestingly, a recent report showed the
same proﬁle expression in the analysis of MDS1/EVI1
(PR positive) versus cEVI1, a region common toMDS1/
EVI1 and EVI1 (PR negative type), using a similar
experimental design (Vinatzer et al., 2003). The expres-
sion of both genes was stronger in the same tissues, with
the only exception of placenta, where MDS1-EVI1 and
cEVI1 are highly expressed, whereas MEL1 and cMEL
are poorly expressed. Fractionated CD34þ progenitor
cell populations indeed showed highMEL1 andMEL1S
expression. Previous studies also conﬁrmed MDS1-
EVI1 and EVI1 expression in early CD34þ progenitor
cells, and suggest that transformation in these progeni-
tors may be the result of a disturbance in the tightly
controlled balance between EVI1 and its fusion tran-
script (Barjesteh van Waalwijk van Doorn-Khosrovani
et al., 2003). We designed a semiquantitative RT–PCR
experiment to compare the expression of cMEL in the
BM of the patient and that of a healthy donor, using
Figure 3 Pattern expression of the MEL1 gene. (a) I. Diagram
showing the structure of the MEL1 and MEL1S transcripts and the
relative location of the primers. Primers MEL1PR-F and MEL1PR-R,
in exon 3 and exon 5, respectively, amplify only the PR-containing
form MEL1; primers MEL1N-F and MEL1N-R, located in exon 12
and exon 13, respectively, amplify the region common to MEL1 and
MEL1S (cMEL). II. Analysis of the expression of MEL1 (lane 1) and
cMEL (MEL1 plus MEL1S) (lane 2) in cDNA from normal CD34þ
cells. M: 1 kb plus molecular weight marker. Lane 3: Negative control.
(b) Expression of MEL1 (I) and expression of cMEL (II) was
performed on cDNA from BM and PB of a healthy donor, normal
uterus, and on a set of normalized, ﬁrst-strand cDNA from eight
different human tissues (Multiple Tissue cDNA Panels I; Clontech,
Basingstoke, UK). (c) Multiplex-PCR to amplifyMEL1 and cMEL in
the same reaction was performed to avoid differences in the
ampliﬁcation level derived from external causes such as variability of
the PCR technique, using a mix of MEL1PR-F, MEL1PR-R,
MEL1N-F and MEL1N-R primers. Multiplex-PCR was performed
in BM of a healthy donor (N) and BM of the patient with t(1;3) (P).
Aliquots of both reactions were taken from cycles 33–41, at the
moment of the denaturation step, in order to ensure that ampliﬁcations
were in the linear phase of ampliﬁcation. Total RNA was extracted
using the RNeasy Mini Kit (Qiagen, Hilden, Germany) from frozen
cell pellets of BM and PB from a healthy donor, uterus and leukemic
cells. The CD34þ cells isolation was performed from mononuclear
cells of normal BM, using the Direct CD34 Progenitor cell isolation kit
(Miltenyi Biotec, Germany). Total RNA (1mg) was used for cDNA
synthesis using SuperScriptt II RNase H-RT (Invitrogen Life
Technologies, Paisley, UK) with random hexamers. RT–PCR reac-
tionswere performed under standard conditions usingAmpliTaqGolds
DNA Polymerase (Applied Biosystems, Foster City, CA, USA),
annealing temperature 651C and 35 cycles. PCR products were
subcloned using the TOPO TA Clonings Kit for Sequencing
(Invitrogen Life Technologies, Paisley, UK). Candidate plasmid clones
were sequenced with the ABI-PRISMt d-Rhodamine Terminator
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) in
an ABI PRISMt 377 DNA Sequencer (Applied Biosystems, Foster
City, CA, USA)
b
Table 1 Oligonucleotide primer sequences
Primer Oligonucleotide sequence (50–30) Gene Nucleotides*
MEL1N-F CCCCAGATCAGCCAATCTCACCA MEL1 2943–2965
MEL1N-R GGTGCCGGTCCAGGTTGGTC MEL1 3142–3123
MEL1PR-F CTGACGGACGTGGAAGTGTCG MEL1 457–477
MEL1PR-R CAGGGGGTAGACGCCTTCCTT MEL1 717–697
BCR-F GAGAAGAGGGCGAACAAG BCR 2889–2906
BCR-R CTCTGCTTAATTCCAGTGGC BCR 3265–3246
*Nucleotide coordinates refer to GenBank Accession numbers NM-022114 (MEL1) and NM-004327 (BCR)
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primers MEL1N-F and MEL1N-R. Ampliﬁcation of
BCR was used as an internal control. The expression
pattern of cMEL in a normal BM in comparison with
BM of the patient was 1/1.28, indicating that this gene is
not overexpressed in our patient with t(1;3). In order to
better discriminate between MEL1 and MEL1S, we
designed a multiplex RT–PCR experiment. In normal
BM, expression of cMEL (MEL1 plus MEL1S) was
stronger than the expression of only MEL1, which
accounted for around half of the total expression. In the
patient sample, both ampliﬁcations had the same
intensity, suggesting that MEL1S could be under-
expressed (Figure 3c). The overexpression of zinc-ﬁnger
proteins lacking the PR domain is considered one of the
main factors in the pathogenesis of some leukemias,
being present or overexpressed in many tumors (Huang,
1999, 2002). The yin-yang mechanism, well studied in
the RIZ gene, was expected to be repeated in other PR
family members. Gene silencing of RIZ1, but not RIZ2,
is common in many types of tumors, and is associated
with promoter DNA methylation; therefore, the PR
domain has been associated with the tumor-suppressor
properties of RIZ1 (Du et al., 2001; Huang, 2002).
Surprisingly, the form without PR (MEL1S) seems to be
poorly expressed in our patient. However, a review of
the literature shows that not all members of the PR-
domain family work in the same way. Two recent
studies detected in 17/21 (81%) patients with t(3;3) or
inv(3) that high EVI1 expression was associated with
high MDS1-EVI1 expression, the form with the PR
domain (Barjesteh van Waalwijk van Doorn-Khosro-
vani et al., 2003; Vinatzer et al., 2003). Moreover, lack
of expression of the PR-lacking form EVI1 has been
reported in several cases with syndrome 3q21q26
(Fichelson et al., 1992; Morishita et al., 1992; Soderholm
et al., 1997; Langabeer et al., 2001), suggesting that the
molecular mechanism of leukemogenesis is not the same
in all patients. Barjesteh van Waalwijk van Doorn-
Khosrovani et al. (2003) described a case with a
translocation involving 3q26, which presented a similar
pattern of expression detected in our case. They
analysed the expression of EVI1, MDS1 and MDS1-
EVI1 by real-time quantitative RT–PCR (RTQ-RT–
PCR) in 319 de novo AML patients, 11 with 3q26
rearrangements. In a patient with RAEB and
t(3;12)(q26;p13), the relative expression of EVI1 when
compared with MDS1-EVI1 was 1/11585. This translo-
cation t(3;12) is different from the classical t(3;3) or
inv(3), although EVI1 (3q26) is also involved. In the
leukemic cells of the case presented here, with MDS and
a t(1;3), MEL1 is expressed and MEL1S, the PR-
domain negative form, seems to be underexpressed.
These data would conﬁrm the results of previous reports
about MDS1-EVI1, and could indicate that different
molecular mechanisms are possible for the members of
the family of PR-domain genes. On the other hand, data
reported by Pekarsky et al. (1997) and Rynditch et al.
(1997) suggest that the 3q21 region is gene rich, and
additional genes instead of RPN1 could be involved in
these rearrangements. GATA-2, located in RP11-
475N22, had been reported as a candidate gene involved
in the 3q21 BP (Wieser, 2002). However, the location of
the BP in our patient suggests that this gene is deleted.
We have analysed the expression of GATA-2 in the
patient BM, and the level of expression was similar
when comparing with normal BM and PB (data not
shown).
In conclusion, the data presented here showed that
MEL1 and MEL1S are widely expressed in tissues,
including PB and BM. We report the molecular
characterization of a novel t(1;3)(p36;q21) in a patient
with MDS (RAEB-2). The clinicopathological features
and the BP on 1p36 are different from cases previously
described, and MEL1 was not overexpressed; instead,
imbalance of a complete MEL1 message with a PR
domain and a short MEL1 message lacking a PR
domain (MEL1S) might be involved in the leukemogen-
esis of this patient. These observations suggest a
heterogeneity in myeloid neoplasias with t(1;3), as has
been reported for cases with 3q21q26 syndrome.
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